drugset / Trial / NCT03847519
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Timeline
- Start
- 2019-02-12
- Primary completion
- 2022-02-22
- Completion
- 2022-02-22
Publications
- Background A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer. Protocol ADXS-503-101, Advaxis Inc, 2018.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADXS-503 | Other / unclassified | 1e+08 unknown | Intravenous |
| Subject | ADXS-503 | Other / unclassified | 5e+08 unknown | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |